10. Antiviral Trials That Will Change Your Practice
Session: Symposium: RCT That Will Change Your Practice
Wednesday, October 3, 2018: 2:40 PM
Room: N 25
Francisco Marty, MD, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA

Dr. Marty is Associate Professor of Medicine at Harvard Medical School and attending physician at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Transplant and Oncology Infectious Diseases. Dr. Marty’s research interests include the clinical epidemiology of infectious diseases in diverse transplant and cancer populations, the development and validation of novel infectious disease diagnostics in immunocompromised hosts, and the conduct of clinical trials for investigational antiinfectives of particular relevance to these populations. He leads the clinical infectious disease consult service for patients at Dana-Farber Cancer Institute. He is editor-in-chief of the Transplant Infectious Disease journal. Dr. Marty received his MD degree from Universidad Central de Venezuela, did his residency in internal medicine at Albert Einstein College of Medicine –where he served as chief resident–, and his fellowship in infectious diseases at the Brigham & Women’s Hospital and Massachusetts General Hospital combined program. He has a Master in Science in Clinical Epidemiology from the Harvard School of Public Health and is a Fellow of the American College of Medicine and the Infectious Diseases Society of America.


Disclosures:

F. Marty, Ansun: Investigator , Research support . Chimerix: Consultant and Investigator , Consulting fee and Research support . Cidara: Investigator , Research support . Fate Therapeutics: Consultant , Consulting fee . Gilead: Investigator , Research support . GlaxoSmithKline: Consultant , Consulting fee . Merck: Consultant and Investigator , Consulting fee and Research support . Roche Molecular Systems: Consultant , Consulting fee . Shire: Consultant and Investigator , Consulting fee and Research support .

See more of: RCT That Will Change Your Practice
See more of: Symposium
<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.